Novo Nordisk A/S (NOVOBN.MX)
| Previous close | 2,150.39 |
| Open | 2,226.00 |
| Bid | 2,226.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 2,226.00 - 2,226.00 |
| 52-week range | 1,340.00 - 2,267.89 |
| Volume | |
| Avg. volume | 2,008 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 35.85 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Ro CEO on GLP-1 drug shortage: US healthcare is '1 of 1'
GLP-1 medication supply constraints have left many patients grappling with the challenge of accessing these highly sought-after drugs. Ro CEO Zach Reitano joins Asking for a Trend to shed light on how his company aims to make supply information more readily available to patients in need. Reitano underscores Ro's core mission of "building goal-oriented healthcare" tailored to the individual needs of its patients. Recently, the company has been dedicating its efforts to addressing obesity, but they have also recognized "a massive shortage" in the availability of GLP-1 drugs. Consequently, Ro has been proactively "building products and services to help patients navigate and manage through these supply challenges." Reitano characterizes the current US healthcare landscape as "one of one," noting that "never before in healthcare has the majority of the US population been eligible for a drug." This situation has led to patients and providers "desperately" wanting access to these therapies, resulting in severe supply-demand dynamics, a challenge Reitano believes could persist for years to come. Reitano explains Ro's goal is to "crowdsource" supply information with its tracker, streamlining the process of accessing these drugs for both patients and healthcare providers. For more expert insight and the latest market action, click here to watch this full episode of Asking for a Trend. This post was written by Angel Smith
- Investor's Business Daily
Is Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally?
Eli Lilly stock broke out after the company reported positive results for Crohn's disease drug. Is LLY stock a buy right now?
- Yahoo Finance Video
Nvidia, advances in cancer research, climate change under Trump: Market Domination
Nvidia (NVDA) continues to dominate the tech sector as the company's shares move past $1,100. The chip giant earned a boost from Elon Musk, who announced that xAI's supercomputer will run on Nvidia technology. Meanwhile, Tesla (TSLA) shareholders are awaiting an important vote on June 13, which will dictate the fate of Musk's proposed pay package of $56 billion. The American Society of Clinical Oncology (ASCO) will hold its annual meeting in Chicago this week, exploring the latest advancements in the cancer research sector. Tom Steyer, Galvanize Climate Solutions Co-Executive Chair, also joins the show to give insight into the state of climate change mitigation under a possible second Trump presidency. For more expert insight and the latest market action, click here.
